FDA approves a new clinical trial for non-healing wounds.
FDA has approved clinical trials in Samford health for its institution second ever adipose-derived stem cell clinical trial which is designed to treat non-healing leg ulcers. The trial has started in September of this year.
The trial includes the study participants with an age above 18 with a leg wound 3- 25 cm and with HBA1C values less than nine and with a leg wound for at least 3 months which is non-healing.“This clinical trial can help explore treatments for people with non-healing wounds, including people who have diabetes and others with conditions that affect their quality of life,” according to David Pearce, Ph.D., executive vice president of innovation and research at Sanford Health
According to the WHO records, there were 398 million people living with diabetes worldwide. Non-healing wounds can be a complication of diabetes, as can several types of vascular disease. In the United States, 2.4 to 4.5 million people live with chronic wounds on some part of their body. Especially for those already battling a disease, the additional stress of caring for a non-healing wound can lead to infection, pain, and continuing chronic health issues.
Stem cell research began in the early 20th century and has shown both ends of a wide spectrum of possibility or as a harm. Advantage as potential cure-all answer for some of our most enduring medical mysteries, or as an inherently immoral practice capable of great harm should it get into the wrong hands.
In recent years, it would seem that stem cell research has become more widely understood and accepted by the general public, and it continues to grow as a body of research with seemingly countless applications.
Stem cells are being researched to cure diabetes, regenerate body parts, and so much more. The study at Sanford Health has yet to be completed, but the FDA’s support of the clinical trial shows that there is growing interest and investment in this avenue of research.